Evidence map›Paper›PMID 41402748›Full record

ReviewBMC nephrology2025

APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.

Oyindamola Christiana Adebayo, Henry Chijindu Okpoli, Joris Vriens, Elena Levtchenko, Lambertus van den Heuvel, Veerle Labarque

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oyindamola Christiana AdebayoCentre of Vascular and Molecular Biology, Department of Cardiovascular Sciences, KU Leuven, Leuven, 3000, Belgium.
Henry Chijindu OkpoliLaboratory of Paediatric Nephrology, Department of Development and Regeneration, KU Leuven, Leuven, 3000, Belgium.
Joris VriensImplantation, Placentation, Pregnancy and Endometriosis Research group (POPPYe), Department of Development and Regeneration, KU Leuven, Leuven, 3000, Belgium.
Elena LevtchenkoDepartment of Paediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, 1105AZ, The Netherlands.
Lambertus van den HeuvelLaboratory of Paediatric Nephrology, Department of Development and Regeneration, KU Leuven, Leuven, 3000, Belgium.
Veerle LabarqueCentre of Vascular and Molecular Biology, Department of Cardiovascular Sciences, KU Leuven, Leuven, 3000, Belgium. veerle.labarque@uzleuven.be.

Funding

Vlaanderen Wetenschap Research Foundation - Flanders 11A5621N and 11A5623NVlaanderen Wetenschap Research Foundation - Flanders G0D1417N, G084515N, and G0A6719N
6 · The paper itself

Abstract

Fifteen years have elapsed since the publication of the seminal work establishing the association between risk variants in the Apolipoprotein L1 (APOL1) gene and kidney disease in individuals of African ancestry. During this period, substantial advancements have been achieved in elucidating the pathophysiology of APOL1-mediated kidney disease, leading to the development of promising therapeutic strategies. In this review, we summarize the key molecular mechanisms driving this disease, including modifiers of onset and progression, and explore relevant disease models. Furthermore, we discuss current therapeutic approaches and outline future research directions.

Indexed as

Apolipoprotein L1Kidney DiseasesHumansAPOL1 protein, humanApolipoprotein L1Apolipoprotein L1GeneticsKidney diseasePodocyte

Identifiers

PMID41402748
PMCPMC12822060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.